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Abstract Recently, the number of studies on male breast
cancer (MBC) has been increasing. However, as MBC is a
rare disease there are difficulties to undertake studies to
identify specific MBC subgroups. At present, it is still lar-
gely unknown whether BRCA-related breast cancer (BC) in
men may display specific characteristics as it is for BRCA-
related BC in women. To investigate the clinical–pathologic
features of MBC in association with BRCA mutations we
established a collaborative Italian Multicenter Study on
MBC with the aim to recruit a large series of MBCs. A total
of 382 MBCs, including 50 BRCA carriers, were collected
from ten Italian Investigation Centres covering the whole
country. In MBC patients, BRCA2 mutations were associ-
ated with family history of breast/ovarian cancer
(p \ 0.0001), personal history of other cancers (p = 0.044)
and contralateral BC (p = 0.001). BRCA2-associated
MBCs presented with high tumor grade (p = 0.001), PR-
(p = 0.026) and HER2? (p = 0.001) status. In a multi-
variate logistic model BRCA2 mutations showed positive
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association with personal history of other cancers (OR
11.42, 95 % CI 1.79–73.08) and high tumor grade (OR 4.93,
95 % CI 1.02–23.88) and inverse association with PR?
status (OR 0.19, 95 % CI 0.04–0.92). Based on immuno-
histochemical (IHC) profile, four molecular subtypes of
MBC were identified. Luminal A was the most common
subtype (67.7 %), luminal B was observed in 26.5 % of the
cases and HER2 positive and triple negative were repre-
sented by 2.1 % and 3.7 % of tumors, respectively.
Intriguingly, we found that both luminal B and HER2
positive subtypes were associated with high tumor grade
(p = 0.003 and 0.006, respectively) and with BRCA2
mutations (p = 0.016 and 0.001, respectively). In conclu-
sion, our findings indicate that BRCA2-related MBCs rep-
resent a subgroup of tumors with a peculiar phenotype
characterized by aggressive behavior. The identification of a
BRCA2-associated phenotype might define a subset of MBC
patients eligible for personalized clinical management.
Keywords Male breast cancer  BRCA1  BRCA2 
Clinical–pathologic features  Molecular subtypes
Introduction
Breast cancer (BC) in men is a rare disease accounting for
\1 % of all cancers in men and \1 % of all BCs. How-
ever, recent epidemiologic studies suggest that the inci-
dence of male breast cancer (MBC) is increasing by 1.1 %
yearly [1, 2].
Compared with female BC (FBC), MBC occurs later in
life, with higher stage and lower grade and more often
displays positive estrogen and progesterone receptors (ER
and PR) status [3, 4].
MBC is likely to be caused by the concurrent effects of
different risk factors, including hormonal, environmental
and particularly genetic risk factors, such as mutations in
BRCA1 and, mainly, BRCA2 genes [5, 6].
It is now well established that in women BRCA-associ-
ated BCs tend to manifest specific genotype–phenotype
correlations [7]. In particular, BRCA1-related BCs have
distinct morphology and show a triple negative (ER-,
PR-, HER2-) phenotype [8]. By contrast, BRCA2-related
BCs are a heterogeneous group not fully characterized [9–
11]. The current knowledge on phenotypic characteristics
of BRCA-associated MBCs is thus far quite limited [5].
Furthermore, while it is generally accepted that FBC is a
heterogeneous disease, whether MBC can be classified into
comprehensive molecular subtypes remains to be eluci-
dated. Indeed, the classification into molecular subtypes
based on immuno-phenotypic features, as proposed for
FBC, is still controversial in MBC. It has been reported that
the luminal A (ER? and/or PR?, HER2-) and luminal B
(ER? and/or PR?, HER2?) are the most common sub-
types in MBC, whereas triple negative (ER-, PR-,
HER2-) and HER2 positive (HER2?/ER-, PR-) are
very rare [12–14].
Overall, knowledge about specific biological and
molecular characteristics of MBC is still largely unknown.
Given the paucity of data and the rarity of the disease, an
effort in establishing collaborative studies is fundamental to
obtain large series of MBCs with detailed epidemiological
and molecular data. Therefore, we established the first Italian
Multicenter Study on MBC to recruit a large series of cases
from the whole Country, with the aim to better examine the
clinical–pathologic features of MBC cases in association
with BRCA mutational status and to identify molecular
subtypes of MBC that could provide useful information for
understanding the pathogenesis of this disease and, eventu-
ally, for clinical management of MBC patients.
Materials and methods
Study population
For this study, 382 MBC cases were enrolled in the
framework of the collaborative Italian Multicenter Study
on MBC. We recruited MBC cases from a total of ten
Italian Investigation Centres in different areas of the
Country including Northern (Istituto Nazionale dei Tumori,
Milan; Istituto Europeo di Oncologia, Milan; Centro di
Riferimento Oncologico, Aviano; Istituto Oncologico
Veneto, Padua; University of Modena and Reggio Emilia,
Modena; Istituto Nazionale per la Ricerca sul Cancro,
Genoa), Central (Cancer Research and Prevention Institute,
Florence; Sapienza University of Rome, Rome), and
Southern (National Cancer Centre, Bari; University of
Palermo, Palermo) Italy.
In this study, we have expanded our previous series of
108 MBC cases from Florence [5] up to 126 MBCs and
enrolled 256 MBC cases from additional nine Italian
Investigation Centres. For each case the following infor-
mation was collected: (1) detailed information on personal
history of other cancers at any site; (2) detailed information
on family history (FH) for cancer at any sites; (3) clinical–
pathologic and molecular data, including histology, grade,
stage, node status, ER, PR, Ki-67, and HER2 status; and (4)
BRCA1 and BRCA2 mutational status. All information was
collected by a geneticist and validated by the relevant
sources, mainly local Cancer and Mortality Registries.
Clinicopathological data were collected through several
mechanisms, including medical records and pathology
reports. For some centers, tumor pathology was indepen-
dently reviewed by study pathologists. Four cases were
excluded from the current analysis because of missing age
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at diagnosis. Then, this study is focused on 378 subjects
with 394 BCs (including 16 subjects with contralateral
BC).
The study was approved by the local ethical committee.
Written informed consent was obtained from all study
subjects.
Molecular characterization
BRCA1 and BRCA2 mutation analysis was performed in
the frame of genetic counselling programs at the center of
origin for all MBC cases. BRCA1/2 mutations were clas-
sified according to their potential functional effect and only
the pathogenic loss-of-function mutations were considered
in the analysis.
ER, PR, Ki-67, and HER2 status of breast tumors were
extracted from medical, pathology, or tumor registry
records or obtained from IHC analysis of sections from
formalin-fixed, paraffin-embedded primary mammary
tumor blocks. HER2 status was assessed by FISH analysis
in ambiguous cases (IHC score = 2?). Cut-off values were
as previously reported [15, 16].
Based on IHC profiles, MBCs were classified according
to the following molecular subtypes: luminal A (ER? and/
or PR?, HER2-), luminal B (ER? and/or PR?, HER2?),
HER2 positive (ER- and PR-, HER2?), and triple neg-
ative (ER-, PR-, HER2-).
Statistical analysis
The association between selected clinical–pathologic and
molecular features and specific groups of MBCs was
assessed by using Fisher’s exact test or v2 for trend as
appropriate (two sided). A multivariate logistic model
including selected parameters (cancer personal history, 1st
degree FH of breast/ovarian cancer, contralateral cancer,
grading, stage, PR and HER2 status) was used to evaluate
the association between the characteristics included in the
model and BRCA2 mutations. p values B0.05 were con-
sidered statistically significant.
Results
Clinical–pathologic characteristics of MBC cases
Clinical characteristics of 378 MBC patients and patho-
logic features of the 394 breast tumors from the 378 MBC
patients included in this study are reported in Table 1.
Age at first MBC diagnosis ranged between 22 and
90 years, with a mean age of 60.9 years (SD: 11.9). Six out
of 139 cases (4.3 %) with a positive FH of breast or ovarian
cancer in first-degree relatives had a first-degree male
Table 1 Clinical–pathologic characteristics of 394 breast tumors
from 378 MBC patients
Characteristicsa N %
Age at diagnosis
\30 3 0.8
31–40 22 5.8
41–50 47 12.4
51–60 98 25.9
61–70 129 34.2
71–80 69 18.3
[80 10 2.6
1st degree FH of breast/ovarian cancer
Negative 239 63.2
Positive 139 36.8
Personal history of other cancers
Negative 321 84.9
Positive 57 15.1
Contralateral BC
No 362 95.9
Yes 16 4.1
BRCA1/2 Mutational status
BRCA1 mutation positive 4 1.1
BRCA2 mutation positive 46 12.2
BRCA1/2 wild-type 328 86.7
Histology
Invasive ductal carcinoma 261 87.0
In situ ductal carcinoma 22 7.3
Medullary carcinoma 1 0.3
Lobular carcinoma 4 1.4
Other 12 4.0
Grading
1 33 12.5
2 153 57.7
3 79 29.8
Stage
I 93 42.3
II 80 36.4
III 40 18.2
IV 7 3.1
ER
Negative 23 8.6
Positive 245 91.4
PR
Negative 43 16.1
Positive 224 83.9
HER2
Negative 139 71.6
Positive 55 28.4
Node status
Negative 145 58.0
Positive 105 42.0
Ki-67
Low 119 58.0
High 86 42.0
a Some data for each parameter are non available
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relative affected with MBC. 57 cases (15.1 %) had one or
two other malignancies, prostate and bladder cancer being
the most frequently reported (14 and 6 cases, respectively).
Moreover, 16 patients (4.1 %) had a diagnosis of contra-
lateral BC. Four MBC patients carried BRCA1 (1.1 %) and
46 BRCA2 (12.2 %) mutations. The majority of tumors
were invasive ductal carcinoma (87 %), followed by ductal
carcinoma in situ (7.3 %). About 58 % of MBCs were G2
and about 80 % of MBCs presented with stages I–II of the
disease. The great majority of tumors were ER? (91.4 %)
and PR? (83.9 %). About 28 % of tumors were HER2?
and 58 % showed negative node status and low prolifera-
tive activity (Ki-67 low).
The 4 BRCA1 mutation positive MBC patients had a
mean age at diagnosis of 62 years (SD: 7.7), and 3 out of 4
have a positive first-degree FH of breast and/or ovarian
cancer. None of the 4 cases had a personal history of other
cancers or a diagnosis of contralateral BC. All 4 BRCA1-
related MBCs were invasive ductal carcinomas with
HER2- status. The majority were G3 (2 out of 3), stage II
(2 out of 3), PR? (3 out of 4), lymph-node positive (2 out
of 3), and Ki-67 high (2 out of 3) tumors. Two of the 4
BRCA1-related MBCs were ER? and a statistically sig-
nificant association (p = 0.037) emerged between BRCA1
mutations and ER- status (data not shown).
The 46 BRCA2 mutation positive MBC patients showed a
mean age at diagnosis of 58.9 years (SD: 11.7), and 31
(67.4 %) had a positive first-degree FH of breast and/or
ovarian cancer (Table 2). 12 cases (26.1 %) had a personal
history of other cancers, mainly prostate cancer (58 %) and 7
patients (15.2 %) had a diagnosis of contralateral BC.
BRCA2-related MBCs were mostly invasive ductal carcino-
mas (88.3 %), G3 (54.8 %), stages I–II (62.5 %), ER?
(89.7 %), PR? (67.9 %), HER2? (63.2 %), lymph-node
positive (56.7 %), and Ki-67 high (56.2 %) tumors. As shown
in Table 2, statistically significant associations emerged
between BRCA2 mutation and FH of breast and/or ovarian
cancer (p \ 0.0001), personal history of other cancers
(p = 0.044), contralateral BC (p = 0.001), tumor grade 3
(p = 0.001), PR- (p = 0.026), and HER2? status (p =
0.001). In a multivariate logistic analysis BRCA2 mutations
showed a positive association with cancer personal history
(OR 11.42; 95 % CI 1.79–73.08; p = 0.01) and tumor grade
3 (OR 4.93; 95 % CI 1.02–23.88; p = 0.048) and, on the
other hand, an inverse association with PR? status (OR 0.19;
95 % CI 0.04–0.92; p = 0.039) (data not shown). In a sep-
arate age-adjusted logistic model the association with cancer
personal history was confirmed (p = 0.017).
Molecular subtypes of MBC cases
The classification into molecular subtypes and their char-
acterization was available for a subset of 189 tumors,
Table 2 Association between clinical–pathologic characteristics and
BRCA2 mutations in MBCs
Characteristicsa BRCA1/2
wt
N (%)
BRCA2 mutation
positive
N (%)
pb
Age at diagnosis
B50 59 (18.0) 13 (28.3)
[50 269 (82.0) 33 (71.7) 0.11
1st degree FH of breast/ovarian cancer
Negative 223 (68.0) 15 (32.6)
Positive 105 (32.0) 31 (67.4) <0.0001
Personal history of other cancers
No 284 (86.6) 34 (73.9)
Yes 44 (13.4) 12 (26.1) 0.044
Contralateral BC
No 319 (97.3) 39 (84.8)
Yes 9 (2.7) 7 (15.2) 0.001
Histology
Invasive ductal
carcinoma
220 (86.6) 30 (88.3)
In situ ductal
carcinoma
20 (7.9) 2 (5.9)
Medullary
carcinoma
0 (0) 1 (2.9)
Lobular carcinoma 4 (1.6) 0 (0) 0.08
Other 10 (3.9) 1 (2.9)
Grading
1–2 169 (74.4) 14 (45.2)
3 58 (25.6) 17 (54.8) 0.001
Stage
I–II 151 (80.7) 15 (62.5)
III–IV 36 (19.3) 9 (37.5) 0.06
ER
Negative 18 (7.8) 3 (10.3)
Positive 213 (92.2) 26 (89.7) 0.71
PR
Negative 33 (14.3) 9 (32.1)
Positive 198 (85.7) 19 (67.9) 0.026
HER2
Negative 126 (75.0) 7 (36.8)
Positive 42 (25.0) 12 (63.2) 0.001
Node status
Negative 129 (61.7) 13 (43.3)
Positive 80 (38.3) 17 (56.7) 0.07
Ki-67
Low 110 (60.1) 7 (43.8)
High 73 (39.9) 9 (56.2) 0.29
BRCA1 mutated cases and secondary tumors were excluded from the
analysis
Statistically significant values (p B 0.05) are indicated in bold
a Some data for each parameter are not available
b p value from Fisher exact test or v2 for trend, as appropriate
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including 4 BRCA1- and 19 BRCA2- associated MBCs,
with complete information on ER, PR, and HER2 status
(Table 3). For 128 out of 189 tumors (67.7 %) a luminal A
subtype (ER? and/or PR?, HER2-) emerged, whereas 50
cases (26.5 %) showed a luminal B (ER? and/or PR?,
HER2?) subtype. HER2 positive (ER- and PR-,
HER2?) and triple negative (ER-, PR-, HER2-) sub-
types were much less common and represented by only 4
(2.1 %) and 7 (3.7 %) tumors, respectively. MBC cases
with luminal B subtype tended to be younger (age
B50 years) than those with luminal A subtype (p = 0.049).
Of the 4 BRCA1-related MBC cases, 3 showed a luminal
A tumor and 1 a triple negative tumor. Of the 19 BRCA2-
related MBCs, 7 were luminal A, 9 luminal B, and 3 HER2
positive. Notably, all 7 cases with triple negative tumors
were BRCA2 mutation negative MBCs. Indeed, BRCA2
mutation positive status was significantly associated with
both HER2 positive subtypes, luminal B and HER2 posi-
tive (p = 0.016 and 0.001, respectively).
The majority of the luminal A tumors (87/119, 73.1 %)
and triple negative tumors (4/6, 66.7 %) had low and
intermediate tumor grades (G1 and G2). In comparison,
high grade (G3) tumors were more frequent in luminal B
(24/45, 53.3 %) and in HER2 positive (4/4; 100 %) sub-
types than in luminal A (p = 0.003 and 0.006,
respectively).
Table 3 Molecular and clinical–pathological characteristics of MBC subtypes
Luminal Ab (total 128) Luminal Bb (total 50) HER2 positiveb (total 4) Triple negativeb (total 7)
N (%) N (%) p* N (%) p* N (%) p*
Age at diagnosis
B50 18 (14.1) 14 (28.0) 1 (25.0) 0 (0)
[50 110 (85.9) 36 (72.0) 0.049 3 (75.0) 0.47 7 (100) 0.59
1st degree FH of breast/ovarian cancer
Negative 86 (67.2) 35 (70.0) 2 (50.0) 6 (85.7)
Positive 42 (32.8) 15 (30.0) 0.86 2 (50.0) 0.60 1 (14.3) 0.43
Personal history of other cancers
No 105 (82.0) 44 (88.0) 4 (100) 6 (85.7)
Yes 23 (18.0) 6 (12.0) 0.38 0 (0) 1.0 1 (14.3) 1.0
BRCA1 mutations
Negative 125 (97.7) 50 (100) 4 (100) 6 (85.7)
Positive 3 (2.3) 0 (0) 0.56 0 (0) 1.0 1 (14.3) 0.19
BRCA2 mutations
Negative 121(94.5) 41 (82.0) 1 (25.0) 7 (100)
Positive 7 (5.5) 9 (18.0) 0.016 3 (75.0) 0.001 0 (0) 1.0
Gradinga
1 ? 2 87 (73.1) 21 (46.7) 0 (0) 4 (66.7)
3 32 (26.9) 24 (53.3) 0.003 4 (100) 0.006 2 (33.3) 0.66
Stagea
I–II 76 (82.6) 31 (75.6) 2 (66.7) 6 (85.7)
III–IV 16 (17.4) 10 (24.4) 0.35 1 (33.3) 0.45 1 (14.3) 1.0
Node statusa
Negative 54 (55.7) 20 (44.4) 0 (0) 4 (80.0)
Positive 43 (44.3) 25 (55.6) 0.28 3 (100) 0.094 1 (20.0) 0.39
Ki-67a
Low 70 (61.9) 20 (51.3) 1 (25.0) 4 (57.1)
High 43 (38.1) 19 (48.7) 0.26 3 (75.0) 0.30 3 (42.9) 1.0
Combined hormonal status (ER, PR, HER2) was available for 189 cases
Statistically significant values (p B 0.05) are indicated in bold
a Some data are not available
b Luminal A: ER? and/or PR?, HER2-; luminal B: ER? and/or PR?, HER2?; HER2 positive: ER-, PR-, HER2?; triple negative: ER-,
PR-, HER2-
* p value from Fisher exact test
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Discussion
In this study, a large series of MBC cases, derived from the
collaborative Italian Multicenter Study on MBC, was
analyzed to investigate the clinical–pathologic features of
MBC in association with BRCA mutations and to charac-
terize immuno-phenotypic subtypes of MBC. A total of
382 MBC cases, including 50 BRCA1/2 mutation carriers,
and their clinical–pathologic characteristics, were collected
from ten Italian Investigation Centres in different areas of
the Country, from Northern to Southern Italy. Despite
differences in study populations and method of collecting
data, the distributions of clinical–pathologic variables
considered in this study (i.e., ER, PR, and HER2) were
generally consistent across different Investigation Centers.
To the best of our knowledge this series represents the
largest MBC series ever assembled in a single country for
which BRCA1 and BRCA2 mutational status and extensive
clinical–pathologic data are available.
As expected, BRCA2 mutations were found to be more
frequent than BRCA1 mutations (12.2 vs 1.1 %). It is
noteworthy that two of the four BRCA1 mutation carriers
found in our series harbor the same mutation that was
previously identified as a founder mutation in Central Italy
[17]. Compared with previous studies, in our series age at
diagnosis was lower and the percentage of cases with a
positive first-degree FH was higher [18–21]. This could
reflect the presence of MBC patients enrolled in a context
of genetic counselling programs, which are more fre-
quently characterized by familial cancer and younger age at
diagnosis. On the other hand, the pathologic characteristics
of male breast tumors, including histology, stage, grade,
and hormone receptor expression were consistent with
former studies (Table 1 in Supplementary material). Thus,
our series can be regarded as representative. Overall,
MBCs present as invasive ductal carcinomas, G2 and
stages I–II disease and express ER and PR.
Taken advantage of our large BRCA1/2 characterized
MBC series we investigated whether specific BRCA-asso-
ciated phenotypes could be identified in MBC. We found
that all four BRCA1-associated MBCs were HER2- with
one case disclosing a triple negative phenotype. The
majority of BRCA1-related MBCs were G3 tumors and
show high proliferative activity. Although based on a few
cases, our results may suggest that BRCA1-related BCs in
men represent a rare event characterized by a phenotype
similar to that observed in women. On the other hand,
BRCA2-associated MBCs display a characteristic BRCA2-
associated BC phenotype not identified in women [11]. In
particular, BRCA2-associated MBCs present with high
tumor grade, the absence of PR expression, and HER2
positive status. Indeed, we have previously reported sta-
tistically significant associations between BRCA2 tumors
and high tumor grade, PR- and HER2? status in a series
of 108 MBCs [5]. In this study, these associations also
emerged either including or excluding (data not shown) the
previous analyzed series thus confirming on a large and
independent series our earlier results.
Here, we also observed that germ-line BRCA2 mutations
are associated with positive personal history of other cancers
and contralateral BC in MBC patients. These findings are
particularly relevant for a personalized clinical management
of MBC patients. In fact, they confirm the needing of an
intensive cancer surveillance, particularly prostate cancer
surveillance [22], after first diagnosis of BC and might raise
the question of performing a bilateral prophylactic mastec-
tomy at the surgery time in BRCA2-associated MBC
patients. Furthermore it is noteworthy that, in a multivariate
logistic analysis, cancer personal history, high tumor grade,
and PR- status emerged to be all statistically associated
with BRCA2 mutations independently. Taking into consid-
eration that the majority of MBCs are PR?, the finding that
PR- MBCs are associated with BRCA2 mutations may have
an important predictive value, thus improving the earlier
detection of BRCA2 mutation carriers.
Based on IHC profile, in this study we also characterized
molecular subtypes of MBC. Luminal A resulted the most
common subtype, followed by luminal B, triple negative,
and HER2 positive subtypes. Overall, our results are con-
sistent with a recent published article showing that luminal
A and, to a lesser extent, luminal B types represent the vast
majority of BC in men whereas triple negative and HER2
positive subtypes are rare [13]. Intriguingly, we found that
both HER2 positive and luminal B subtypes were associ-
ated with BRCA2 mutations. Notably, all previous studies
were performed in MBCs not characterized for BRCA2
mutations, and, based on BRCA2 mutation frequency and
on the number of cases analyzed, BRCA2-related MBCs
were likely rare, if any, in the published series. This could
probably explain why HER2 positive and luminal B sub-
types have been, thus far, infrequently reported in MBC
[12–14]. We also found a statistically significant associa-
tion between both HER2 positive and luminal B subtypes
with high tumor grade. Taken together, these data suggest
that in men luminal B and HER2 positive BC subtypes are
associated with characteristic unfavorable prognostic fac-
tors, such as high grade, and are BRCA2-related BCs.
Although we had a large sample size, missing data for
molecular markers may have limited the power of our
findings. Thus, a further effort in collecting more MBC
cases together with their epidemiological and molecular
features is currently in progress.
In conclusion, our findings indicate that BRCA2-related
MBCs represent a subgroup of tumors with a peculiar
phenotype characterized by aggressive behavior. The
identification of a BRCA2-associated phenotype might
416 Breast Cancer Res Treat (2012) 134:411–418
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define a subset of MBC patients eligible for personalized
clinical management and for targeted therapy. Overall,
results from this study may be helpful in improving the
understandings and the management of this rare disease
and deserve to be confirmed in large international collab-
orative studies.
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